BackBarinthus Biotherapeutics Plc. Overview

Barinthus Biotherapeutics Plc. Total Liabilities

Latest total liabilities for BRNS: $26M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$25.66M
2.80% YoYΔ $-738000.00 vs prior year quarter

Peer average

Loading

Barinthus Biotherapeutics Plc. Total Liabilities History

Loading

Barinthus Biotherapeutics Plc. vs. peers: Total Liabilities Comparison

Loading

Barinthus Biotherapeutics Plc. Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Barinthus Biotherapeutics Plc. (BRNS) FAQ

As of the most recent data (March 2026), BRNS shows a total liabilities of $26M. That compares with $26M in the prior-year period — down 2.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BRNS's total liabilities is now $26M (was $26M) — a 2.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Barinthus Biotherapeutics Plc. is outperforming or lagging.

Tracking BRNS's total liabilities over time shows whether Barinthus Biotherapeutics Plc. is scaling, shrinking, or reshaping that part of the business. The current reading is $26M That compares with $26M in the prior-year period — down 2.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Barinthus Biotherapeutics Plc.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $26M) with ownership activity and broader fundamentals.

Barinthus Biotherapeutics Plc.'s total liabilities is $26M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.